Suzetrigine: A New Frontier in Acute Pain Relief

The Promise of Suzetrigine

Acute pain after surgery affects millions of patients each year and often requires strong medication to control it. Traditional opioid drugs are effective options to control pain, but they are associated with addiction, sedation, and other serious side effects. A new medication called suzetrigine has been developed to treat acute pain without the use of opioids.

What the Trials Point To

A large scientific study tested suzetrigine in adults who experienced acute pain after surgery. The study included patients who had two different types of surgeries that generally cause moderate to severe pain. Patients in the study were given either suzetrigine, an opioid pain or a placebo, which is a pill with no medication in it. Doctors then measured how much pain each patient had over the next two days after surgery.

The study importantly determined that people who took suzetrigine had much less pain than people who took the placebo. Many patients felt relief faster when they took suzetrigine. Additionally, the pain relief from suzetrigine was found to be about the same as the pain relief from the opioid medicine. The study also showed that suzetrigine was safe and well tolerated. Most side effects were mild and included things like headache or nausea. The medicine did not cause serious problems like slowed breathing or addiction, which are risky side effects of opioid medications.

The Science of Suzetrigine Differs from Opioids

Suzetrigine works in a different way from opioids. It blocks pain signals in the nerves before they ever have the chance to reach the brain. Because suzetrigine does not work in the brain like opioids, it does not cause a “high” or dependence that can happen with opioid medications.

Final Takeaways about Suzetrigine

This study shows that suzetrigine can help control pain after surgery in a safer way than opioid medications. It gives patients and doctors a new option for acute pain relief without the risks that comes with opioids.

Citation:

Bertoch T, D'Aunno D, McCoun J, Solanki D, Taber L, Urban J, Oswald J, Swisher MW, Tian S, Miao X, Correll DJ, Negulescu P, Bozic C, Weiner SG. Suzetrigine, a Nonopioid Na V 1.8 Inhibitor for Treatment of Moderate-to-severe Acute Pain: Two Phase 3 Randomized Clinical Trials. Anesthesiology. 2025 Jun 1;142(6):1085-1099. doi: 10.1097/ALN.0000000000005460. Epub 2025 Mar 21. PMID: 40117446; PMCID: PMC12061372.

Assessed and Endorsed by the MedReport Medical Review Board